

Edgar Filing: PHILLIPS 66 PARTNERS LP - Form FWP

PHILLIPS 66 PARTNERS LP
Form FWP
February 19, 2015

Issuer Free Writing Prospectus dated February 18, 2015

Relating to Preliminary Prospectus Supplement dated February 18, 2015

Registration Statement No. 333-197797

Phillips 66 Partners LP

\$300,000,000 2.646% SENIOR NOTES DUE 2020
\$500,000,000 3.605% SENIOR NOTES DUE 2025
\$300,000,000 4.680% SENIOR NOTES DUE 2045

PRICING TERM SHEET

Issuer:	Phillips 66 Partners LP		
Trade Date:	February 18, 2015		
Settlement Date:	February 23, 2015 (T+3)		
Net Proceeds (before expenses):	\$1,092,019,000		
Title of Securities:	2.646% Senior Notes Due 2020	3.605% Senior Notes Due 2025	4.680% Senior Notes Due 2045
Principal Amount:	\$300,000,000	\$500,000,000	\$300,000,000
Coupon:	2.646%	3.605%	4.680%
Maturity Date:	February 15, 2020	February 15, 2025	February 15, 2045
Public Offering Price:	100.000% of principal amount, plus accrued interest, if any, from February 23, 2015	99.967% of principal amount, plus accrued interest, if any, from February 23, 2015	99.953% of principal amount, plus accrued interest, if any, from February 23, 2015
Benchmark Treasury:	1.250% due January 31, 2020	2.000% due February 15, 2025	3.000% due November 15, 2044
Spread to Benchmark Treasury:	+112 bps	+152 bps	+197 bps
Benchmark Price/Yield:	98-22; 1.526%	99-06+; 2.089%	105-26+; 2.713%
Reoffer Yield:	2.646%	3.609%	4.683%

Edgar Filing: PHILLIPS 66 PARTNERS LP - Form FWP

Interest Payment Dates:	February 15 and August 15, commencing August 15, 2015	February 15 and August 15, commencing August 15, 2015	February 15 and August 15, commencing August 15, 2015
Interest Record Dates:	February 1 and August 1	February 1 and August 1	February 1 and August 1
Make-Whole Call:	At any time prior to January 15, 2020, at T + 20 bps.	At any time prior to November 15, 2024, at T + 25 bps.	At any time prior to August 15, 2044, at T + 30 bps.
Par Call:	On or after January 15, 2020	On or after November 15, 2024	On or after August 15, 2044
Expected Ratings*:	Moody s: Baa3	Moody s: Baa3	Moody s: Baa3
	Standard & Poor s: BBB	Standard & Poor s: BBB	Standard & Poor s: BBB

* These expected ratings are not a recommendation to buy, sell or hold the notes offered hereby. The ratings may be subject to revision or withdrawal at any time and should be evaluated independently of any other rating.

Distribution:	SEC Registered	SEC Registered	SEC Registered
CUSIP / ISIN:	CUSIP: 718549 AA6 ISIN: US718549AA60	CUSIP: 718549 AB4 ISIN: US718549AB44	CUSIP: 718549 AC2 ISIN: US718549AC27
Underwriters Fee:	0.600% of principal amount	0.650% of principal amount	0.875% of principal amount
Underwriters	<i>Joint Book-Running Managers</i>		
(for each series of notes):	RBS Securities Inc. Barclays Capital Inc. Goldman, Sachs & Co. RBC Capital Markets, LLC		

Edgar Filing: PHILLIPS 66 PARTNERS LP - Form FWP

Passive Book-Runners

Deutsche Bank Securities Inc.

DNB Markets, Inc.

J.P. Morgan Securities LLC

Merrill Lynch, Pierce, Fenner & Smith

Incorporated

PNC Capital Markets LLC

Co-Managers

BNP Paribas Securities Corp.

Lloyds Securities Inc.

Mizuho Securities USA Inc.

Morgan Stanley & Co. LLC

Scotia Capital (USA) Inc.

Wells Fargo Securities, LLC

The Issuer has filed a registration statement (including a prospectus) with the U.S. Securities and Exchange Commission (the SEC) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at <http://www.sec.gov>. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling RBS Securities Inc. toll-free at 1-866-884-2071, Barclays Capital Inc. toll-free at 1-888-603-5847, Goldman, Sachs & Co toll-free at 1-866-471-2526 or RBC Capital Markets, LLC toll-free at 1-866-375-6829.

This Pricing Supplement is qualified in its entirety by reference to the Preliminary Prospectus Supplement dated February 18, 2015 (the Preliminary Prospectus Supplement). The information in this Pricing Supplement supplements the Preliminary Prospectus Supplement and supersedes the information in the Preliminary Prospectus Supplement to the extent inconsistent with the information in the Preliminary Prospectus Supplement.
